Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Vincerx Pharma, Inc. (LSAC)
|
Add to portfolio |
|
|
|
| Price: |
$10.03
| | Metrics |
| OS: |
21.4
|
M
| |
|
|
| Market cap: |
$214
|
M
| |
|
|
|
Net cash:
|
$27.4
|
M
| |
$1.28
|
per share
|
|
EV:
|
$187
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Jun-30-20 |
| Revenues | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 |
| Selling, general and administrative | | | 0.2 |
| Research and development | 40.1 | 2.1 | |
| General and administrative | 22.6 | 3.6 | |
| EBIT | -62.7 | -10.7 | -0.2 |
| Pre-tax income | -39.3 | -16.6 | -0.1 |
| Income taxes | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | |
| Net income | -39.3 | -16.6 | -0.1 |
| |
| Diluted EPS | ($2.29) | ($3.16) | ($0.01) |
| Shares outstanding (diluted) | 17.2 | 5.3 | 8.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|